Martina Benesova

This inventor holds 9 USPTO granted patents and 9 published patent applications and 4 EPO patents. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg, Ruprecht-Karls-Universitaet Heidelberg. Active years: 2018-2024.

USPTO Granted Patents = 9 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 8.0

ph-index = 5

Forward Citations = 50(Granted Patents)

Location History:

Heidelberg, DE (2018 - 2024)
Neckarsteinach, DE (2020 - 2024)

Company Filing History:

7 out of 159

Deutsches Krebsforschungszentrum

patents

4 out of 64

Ruprecht-Karls-Universitat Heidelberg

patents

3 out of 23

Ruprecht-Karls-Universitaet Heidelberg

where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054458 - F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer (2024-08-06),

2. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer (2024-04-09),

3. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2024-03-19),

4. 11638765 - Double-labeled probe for molecular imaging and use thereof (2023-05-02),

5. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2021-06-29),

6. 10815200 - 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer (2020-10-27),

7. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-11-12),

8. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-09-03),

9. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2018-07-10),

I specialize in the sphere of innovations, inventions, inventors, patent attorneys, assignees, and patents. If you have any questions related to these topics, feel free to ask.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]

9 patents pending:

Please report any incorrect information to [email protected]

4 patents (EPO):

Please report any incorrect information to [email protected]

9 patents pending (EPO):

Please report any incorrect information to [email protected]